Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Amy Perrin-Ross

Maywood, IL Nurse Practitioner

CMS profile 11419709

2160 S 1St Ave, Maywood, IL 60153

Open in the dashboard

General payments

$192,826

333 records reported · program years 2022–2025

Research payments

$12,911

Paid to them · 11 records reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Perrin-Ross of Maywood, IL is reported in the CMS Open Payments database as having received $192,826 across 333 general payments and $12,911 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $70,878 109
2025 Research $274 1
2024 General $65,544 121
2023 General $25,670 61
2023 Research $10,270 9
2022 General $30,734 42
2022 Research $2,367 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Perrin-Ross
  • Illinois median
  • Middle half of Illinois
  • National median

In program year 2025, general payments to Amy Perrin-Ross were reported at $70,878. Among 38,505 Illinois profiles paid that year, the median was $163 and the middle half received between $50 and $568.

Show as a table
Year Amy Perrin-Ross Illinois median Middle half National median
2019 $0 $151 $49–$575 $163
2020 $0 $105 $32–$363 $114
2021 $0 $124 $36–$426 $132
2022 $30,734 $138 $41–$499 $149
2023 $25,670 $148 $45–$517 $160
2024 $65,544 $154 $47–$535 $164
2025 $70,878 $163 $50–$568 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. UCB, Inc. $35,459 86 payments
  2. E.R. Squibb & Sons, L.L.C. $32,741 61 payments
  3. Amgen Inc. $32,166 69 payments
  4. Ucb SA $32,059 12 payments
  5. Janssen Pharmaceuticals, Inc $16,414 19 payments
  6. F. Hoffmann-La Roche AG $9,612 13 payments
  7. Celgene Corporation $8,212 19 payments
  8. Novartis Pharmaceuticals Corporation $5,033 8 payments
  9. Alexion Pharmaceuticals, Inc. $4,876 11 payments
  10. Genentech USA, Inc. $4,602 7 payments
  11. Other $11,654 28 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $77,790 55 payments
  2. Consulting Fee $69,374 47 payments
  3. Travel and Lodging $40,855 124 payments
  4. Food and Beverage $4,789 106 payments
  5. Education $18 1 payment
Products named General payments · program years 2022–2025
  1. ZEPOSIA $37,828 75 payments
  2. UPLIZNA $26,127 58 payments
  3. Rystiggo $18,429 57 payments
  4. Ponvory $14,796 17 payments
  5. Zilbrysq Neurology $8,291 15 payments
  6. OCREVUS $6,002 9 payments
  7. KESIMPTA Neurology $5,033 8 payments
  8. KESIMPTA Neuroscience $4,485 1 payment
  9. Zilbrysq Neurology $4,258 11 payments
  10. ULTOMIRIS $3,997 8 payments
  11. Other $1,726 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2022–2025
  1. F. Hoffmann-La Roche AG $10,194 8 payments
  2. Novartis Pharma AG $2,443 2 payments
  3. Novartis Pharmaceuticals Corporation $274 1 payment

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record